ECM Prosthetic Valve Tissue Regeneration

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Conventional prosthetic heart valves face issues such as tissue calcification, requirement for anticoagulation agents causing side effects, and the need for open heart surgery, along with the inability to remodel into normal tissue capable of regeneration and self-repair.

Innovation Solution

Development of prosthetic tissue valves with continuous conical shaped tubular members made from extracellular matrix (ECM) compositions, which include biologically active agents and pharmacological agents to induce host tissue proliferation, bioremodeling, and regeneration, and are designed for secure attachment to cardiovascular structures without the need for cardiopulmonary bypass.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If conventional prosthetic valves are used, then valve replacement can be achieved, but tissue calcification and deterioration occur over time

Engineering Contradiction:
Improvevalve durabilityVSAvoidtissue calcification
Core Design Contradiction:
Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent changes the material parameters of the prosthetic valve by using glutaraldehyde cross-linked tissue instead of conventional materials, which fundamentally alters the biochemical properties to prevent calcification and deterioration while maintaining structural integrity over time

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite structure by combining glutaraldehyde cross-linked tissue with a support structure, forming a composite material that exhibits both the biological compatibility of tissue and the mechanical strength needed to resist calcification and wear

Inventive Principle:
Principle #40Composite materials

2Reliability

If mechanical valves are used, then durable valve replacement is achieved, but anticoagulation agents are required causing side effects

Engineering Contradiction:
Improvevalve performanceVSAvoidside effects from anticoagulation
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the mechanical valve system with a bioprosthetic system using glutaraldehyde cross-linked tissue, which eliminates the need for anticoagulation therapy while maintaining reliable valve function through the cross-linked tissue's inherent durability and resistance to degradation

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

3Adaptability or versatility

If conventional prosthetic valves are used, then valve replacement is achieved, but the valves cannot remodel into normal tissue capable of regeneration

Engineering Contradiction:
Improvetissue regeneration capabilityVSAvoidvalve structure stability
Core Design Contradiction:
Adaptability or versatilityVSStability of the object's composition

Solution Approach 1:

The invention introduces dynamic properties to the prosthetic valve by using glutaraldehyde cross-linked tissue that can undergo controlled remodeling and adaptation over time, allowing the valve to integrate with host tissue and potentially regenerate while maintaining structural stability through the cross-linked framework

Inventive Principle:
Principle #15Dynamics

4Reliability

If conventional surgical methods are used, then valve replacement is achieved, but open heart surgery with cardiopulmonary bypass is required

Engineering Contradiction:
Improvesurgical outcomeVSAvoidsurgical procedure complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs a flexible thin-film structure made of glutaraldehyde cross-linked tissue that can be delivered through minimally invasive approaches, eliminating the need for open heart surgery and cardiopulmonary bypass while ensuring reliable valve replacement through the film's ability to self-seal and conform to the valve annulus

Inventive Principle:
Principle #30Flexible shells and thin films

Data Source

PatentEP3380044B1Prosthetic tissue valves
Publication Date: 2020.01.29 CORMATRIX CARDIOVASCULAR INC
  • EP3380044B1 patent drawingFigure 1A~1B
  • EP3380044B1 patent drawingFigure 1C
  • EP3380044B1 patent drawingFigure 1D~1F

AI summary

A prosthetic valve comprising a conical shaped member comprising an extracellular matrix (ECM) composition, the conical shaped member comprising a sheet member having a plurality of slit regions that are configured to open during expansion of the sheet member that is induced by positive fluid flow through the sheet member and close during contraction of the sheet member that is induced by negative fluid flow through the sheet member.